Mon, Feb. 22, 4:14 PM
- ResMed (NYSE:RMD) acquires privately held Brighttree, a developer of business management and clinical cloud-based software applications for the post-acute care industry, for $800M in cash. ResMed will fund most of the purchase with debt.
- The transaction will be immediately accretive to gross margins and non-GAAP EPS. It includes an estimated $300M from an anticipated future tax benefit, expected to positively affect ResMed's cash flow over 15 years.
- Brightree booked $113M in sales and $43M in EBITDA last year.